Trans Medics Group, Inc. TMDX
We take great care to ensure that the data presented and summarized in this overview for TransMedics Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMDX
View all-
Vanguard Group Inc Valley Forge, PA3.57MShares$508 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.11MShares$442 Million0.06% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$376 Million0.01% of portfolio
-
State Street Corp Boston, MA1.31MShares$185 Million0.0% of portfolio
-
Fil LTD Hamilton, D01.23MShares$174 Million0.09% of portfolio
-
Macquarie Group LTD Australia, C31.12MShares$158 Million0.09% of portfolio
-
Braidwell LP Stamford, CT855KShares$121 Million3.53% of portfolio
-
Credit Suisse Ag Zurich, V8848KShares$120 Million0.06% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL796KShares$113 Million1.02% of portfolio
-
Geode Capital Management, LLC Boston, MA793KShares$113 Million0.0% of portfolio
Latest Institutional Activity in TMDX
Top Purchases
Top Sells
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Insider Transactions at TMDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2025
|
Anil P. Ranganath |
SELL
Open market or private sale
|
Direct |
686
-4.69%
|
$95,354
$139.8 P/Share
|
|
May 27
2025
|
Edward M Basile |
SELL
Open market or private sale
|
Direct |
5,000
-63.56%
|
$630,000
$126.45 P/Share
|
|
May 27
2025
|
Edward M Basile |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+38.86%
|
$0
$0.7 P/Share
|
|
May 23
2025
|
David Weill |
SELL
Open market or private sale
|
Direct |
732
-5.69%
|
$90,036
$123.88 P/Share
|
|
May 22
2025
|
Thomas James Gunderson |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+34.46%
|
-
|
|
May 22
2025
|
Merilee Raines |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+34.46%
|
-
|
|
May 22
2025
|
James R Tobin |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+34.46%
|
-
|
|
May 22
2025
|
Stephanie Lovell |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+34.46%
|
-
|
|
May 22
2025
|
Edward M Basile |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+42.68%
|
-
|
|
May 22
2025
|
David Weill |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+14.23%
|
-
|
|
May 22
2025
|
Edwin M Kania Jr |
BUY
Grant, award, or other acquisition
|
Direct |
2,134
+0.81%
|
-
|
|
May 09
2025
|
Edward M Basile |
SELL
Open market or private sale
|
Direct |
6,000
-89.13%
|
$690,000
$115.63 P/Share
|
|
May 09
2025
|
Edward M Basile |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+47.13%
|
$0
$0.7 P/Share
|
|
Mar 03
2025
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,407
-6.26%
|
$182,932
$76.43 P/Share
|
|
Feb 25
2025
|
Waleed H Hassanein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
59,781
+32.99%
|
-
|
|
Feb 24
2025
|
Gerardo Hernandez Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,521
+18.05%
|
-
|
|
Feb 24
2025
|
Anil P. Ranganath |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+27.79%
|
-
|
|
Feb 24
2025
|
Nicholas Corcoran |
BUY
Grant, award, or other acquisition
|
Direct |
12,676
+27.29%
|
-
|
|
Feb 24
2025
|
Tamer I Khayal Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,606
+31.41%
|
-
|
|
Jan 07
2025
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,083
-4.94%
|
$86,640
$80.05 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 127K shares |
|---|---|
| Exercise of conversion of derivative security | 135K shares |
| Bona fide gift | 18K shares |
| Open market or private sale | 159K shares |
|---|---|
| Bona fide gift | 18K shares |